Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Bristol-Myers Squibb and uniQure announce heart disease research alliance

Bristol-Myers Squibb and uniQure announce heart disease research alliance

8th April 2015

Bristol-Myers Squibb has announced a new collaboration with uniQure on the development of new heart disease therapies.

The deal will provide Bristol-Myers Squibb with exclusive access to uniQure's gene therapy technology platform for multiple targets in cardiovascular diseases, with the collaborative work to commence during the second quarter of 2015.

Included in the collaboration will be uniQure's proprietary gene therapy programme for congestive heart failure, which works by restoring the heart's ability to synthesise S100A1, a calcium sensor and master regulator of heart function.

Bristol-Myers Squibb will lead development and regulatory activities across all programmes and be responsible for all research and development costs and commercialisation, while uniQure will lead discovery efforts and be responsible for manufacturing of clinical and commercial supplies.

Dr Carl Decicco, head of discovery at Bristol-Myers Squibb's research and development unit, said: "Collaborating with uniQure, a clear leader in the field with an innovative and validated gene therapy platform, further strengthens our capability to bring forward transformational new therapeutics for difficult-to-treat diseases."

Last month, Bristol-Myers Squibb signed an exclusive agreement with Bavarian Nordic to license and commercialise Prostvac, a prostate-specific antigen-targeting cancer immunotherapy.ADNFCR-8000103-ID-801782713-ADNFCR

We currently have 10 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.